Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 6/20 | 0.64 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 4/20 | 0.52 |
| ▸ | PLG | P00747 | 2/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
| ▸ | KLK1 | P06870 | 1/20 | 0.52 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.49 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238372 | 0.88 | PRMT1 (0.64) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL8235636 | 0.79 | PRMT1 (1.00) | PRMT1 | |
| Stilbamidine SCHEMBL208655 | 0.75 | PRMT1 (1.00) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Stilbamidine SCHEMBL889782 | 0.75 | PRMT1 (1.00) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Stilbamidine SCHEMBL3932459 | 0.73 | PRMT1 (0.95) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL12348376 | 0.73 | PLG (0.68) | PRMT1PRMT5PLAUPLGKLK1 | |
| Dapi SCHEMBL235865 | 0.72 | PRMT5 (0.83) | PRMT1PRMT5PLAUPLGPRMT3 | |
| Dapi SCHEMBL28176609 | 0.72 | PRMT5 (0.83) | PRMT1PRMT5PLAUPLGPRMT3 | |
| Dapi SCHEMBL29350295 | 0.72 | PRMT5 (0.83) | PRMT1PRMT5PLAUPLGPRMT3 | |
| Stilbamidine SCHEMBL871695 | 0.71 | PRMT1 (0.91) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | disclosed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | disclosed |
| US-7825154-B2 | Small molecule inhibitors of botulinum neurotoxins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825154-B2 | Small molecule inhibitors of botulinum neurotoxins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2010-11-02 | — | — | US | disclosed |
| US-7781183-B2 | Inhibition of anthrax lethal factor protease | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781183-B2 | Inhibition of anthrax lethal factor protease | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | disclosed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ACHE, CTRL, MMP2 | PRMT1 1502/4885PRMT5 1197/4885ALDH1A1 1028/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | PRMT1 2768/4885PRMT5 2533/4885ALDH1A1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.